Search
Squalamine
go.drugbank.com/drugs/DB06461InvestigationalCategories: Compounds used in a research, industrial, or household settingPafuramidine
go.drugbank.com/drugs/DB06532InvestigationalPafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.
Ceftaroline fosamil
go.drugbank.com/drugs/DB06590ApprovedInvestigationalCeftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market. … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis